It is postulated that activation of ACE2/ANG 1-7/Mas arm of the RAS, and strictly augmentation of ANG 1-7 concentrations, could be a novel therapeutic tool for cardio-renal diseases, particularly hypertension, HF and CKD [14–16]. Here, ACE2 is linked to chronic kidney disease.